share_log

百济神州(688235.SH)：欧盟委员会批准百泽安用于三项非小细胞肺癌适应症的一线及二线治疗

BeiGene (688235.SH): European Commission approves Baizean for first-line and second-line treatment of three non-small cell lung cancer indications

Gelonghui Finance ·  Apr 23 06:24

Gelonghui, April 23 | BeiGene (688235.SH) announced recently that the European Commission has granted marketing license to Baizean (tirelizumab injection) and approved it for first-line and second-line treatment of three non-small cell lung cancer (NSCLC) indications: combination paclitaxel and carboplatin or injectable paclitaxel (albumin conjugated type) and carboplatin for use in first-line treatment of adult patients with platinum-containing radiotherapy; combined with chemoplatine and chemoplatine Used for PD-L1 expression ≥ 50% and no epidermis First-line treatment for adult patients with locally advanced or metastatic non-squamous non-small cell lung cancer with positive growth factor receptor (EGFR) or anaplastic lymphoma kinase (ALK) mutations and not suitable for surgical resection or platinum-containing chemoradiotherapy; monotherapy for adult patients with locally advanced or metastatic NSCLC after previous platinum-containing medications. NSCLC patients with EGFR mutation or ALK mutation positive should have received targeted therapy before receiving tirelizumab therapy.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment